Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma
PD-L1 seems a reliable predictive biomarker in MM, when assessed on tissue obtained within 90 days prior to ICI initiation. Non-nodal metastatic sites appear preferable.
Authors
- Kasper Madsen (ORCID: https://orcid.org/0009-0006-7612-3906)
- A.A. Luczak
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0002-4063-3561)
- Cecilie Dam Vestergaard
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.ejca.2025.115402
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Bristol-Myers Squibb
- Les Laboratories Pierre Fabre
- Novo Nordisk